The S1P 1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment

Cellular and Molecular Immunology

Volumn 12, Issue 6, 2015, Pages 681-691

  Cheng, Qiao ^a   Ma, Shoubao ^a   Lin, Dandan ^a   Mei, Yu ^a   Gong, Huanle ^a   Lei, Lei ^a   Chen, Yuanyuan ^a   Zhao, Ye ^a   Hu, Bo ^a   Wu, Yan ^a   Yu, Xiao ^a   Zhao, Lixiang ^a   Liu, Haiyan ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Chemokine; Monocyte MacrophageI; S1P; S1P receptor agonist

Indexed keywords

2 [4 [5 (3,4 DIETHOXYPHENYL) 1,2,4 OXADIAZOL 3 YL] 2,3 DIHYDRO 1H INDEN 1 YL AMINO]ETHANOL; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; 2-(4-(5-(3,4-DIETHOXYPHENYL)-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL AMINO)ETHANOL; CCL2 PROTEIN, HUMAN; CCL7 PROTEIN, HUMAN; INDAN DERIVATIVE; OXADIAZOLE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION INHIBITION; MONOCYTE; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; UMBILICAL VEIN ENDOTHELIAL CELL; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; MACROPHAGE; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOKINE CCL7; DISEASE MODELS, ANIMAL; FINGOLIMOD HYDROCHLORIDE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDANS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MONOCYTES; OXADIAZOLES; RECEPTORS, LYSOSPHINGOLIPID; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; WHOLE-BODY IRRADIATION;

EID: 84946018152     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.59     Document Type: Article

References (51)

1. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3-10.
2. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, Kellner ES, et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol 2009; 175: 2023-2033.
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340-352.
4. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004; 279: 15396-5401.
5. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
6. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008; 8: 753-763.
7. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146: 980-991.
8. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
9. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
10. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003; 554: 189-193.
11. Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006; 107: 1454-1458.
12. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011; 108: 751-756.
13. Rosen H, Liao J. Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm. Curr Opin Chem Biol 2003; 7: 461-468.
14. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004; 45: 991-997.
15. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-897.
16. Brinkmann V, Wilt C, Kristofic C, Nikolova Z, Hof RP, Chen S, et al. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 2001; 33: 3078-3080.
17. Chiba T, Yokosuka O, Goto S, Fukai K, Imazeki F, Kohno Y, et al. Clinicopathological features in patients with hepatic graft-versushost disease. Hepatogastroenterology 2005; 52: 1849-1853.
18. Hashimoto D, Asakura S, Matsuoka K, Sakoda Y, Koyama M, Aoyama K, et al. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur J Immunol 2007; 37: 271-281.
19. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005; 2: 439-448.
20. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graftversus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003; 111: 659-669.
21. Yopp AC, Ledgerwood LG, Ochando JC, Bromberg JS. Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant 2006; 20: 788-795.
22. Budde K, Schmouder RL, Nashan B, Brunkhorst R, Lücker PW, Mayer T, et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 2003; 3: 846-854.
23. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309: 758-768.
24. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 2008; 74: 1308-1318.
25. Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 2005; 201: 291-301.
26. Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Graler M, Heusch G, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011; 108: 314-323.
27. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate-modifiers of lymphocyte migration. N Engl J Med 2006; 355: 1088-1091.
28. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, et al. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res 2005; 96: 913-920.
29. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, et al. HDL-Associated lysosphingolipids inhibit NAD(P)H oxidasedependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28: 1542-1548.
30. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-77.
31. Martini S, Kramer S, Loof T, Wang-Rosenke Y, Daig U, Budde K, et al. S1P modulator FTY720 limits matrix expansion in acute anti-Thy1 mesangioproliferative glomerulonephritis. Am J Physiol Renal Physiol 2007; 292: F1761-F1770.
32. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20: 16-24.
33. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 2008; 210: 681-690.
34. Hla T, Venkataraman K, Michaud J. The vascular S1P gradientcellular sources and biological significance. Biochim Biophys Acta 2008; 1781: 477-482.
35. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease af ter al logeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-123.
36. Robb RJ, Hill GR. The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood 2012; 119: 5351-5358.
37. Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, Cameron MD, et al. S1P1 receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol Pharmacol 2012; 81: 166-174.
38. Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E, Weber C, et al. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R2/2) mice. Vascul Pharmacol 2012; 57: 56-64.
39. Huu DL, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, et al. FTY720 ameliorates murine sclerodermatous chronic graftversus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum 2013; 65: 1624-1635.
40. Song J, Ito T, Matsuda C, Miao G, Tanemura M, Nishida T, et al. Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation. Clin Exp immunology 2006; 146: 85-92.
41. Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graftversus-host disease (GVHD). Blood 2007; 110: 3480-3488.
42. Toubai T, Shono Y, Nishihira J, Ibata M, Suigita J, Kato N, et al. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol 2009; 31: 161-168.
43. Toubai T, Tanaka J, Nishihira J, Ohkawara T, Hirate D, Kondo N, et al. Effect of macrophage migration inhibitory factor (MIF) on acute graftversus-host disease in a murine model of allogeneic stem cell transplantation. Transpl Immunol 2006; 16: 117-124.
44. Nishiwaki S, Terakura S, Ito M, Goto T, Seto A, Watanabe K, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graftversus-host disease. Blood 2009; 114: 3113-3116.
45. Duong CQ, Bared SM, Abu-Khader A, Buechler C, Schmitz A, Schmitz G. Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages. Biochim Biophys Acta 2004; 1682: 112-119.
46. Weigert A, Weis N, Brune B. Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology 2009; 214: 748-760.
47. OSullivan C, Dev KK. The structure and function of the S1P1 receptor. Trends Pharmacol Sci 2013; 34: 401-412.
48. Dong J, Wang H, Wu G, Zhao J, Zhang L, Zuo L, et al. Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice. Clin Exp Immunol 2014; 177: 94-101.
49. Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ. AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 2009; 216: 59-65.
50. Healy LM, Sheridan GK, Pritchard AJ, Rutkowska A, Mullershausen F, Dev KK. Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br J Pharmacol 2013; 169: 1114-1129.
51. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009; 5: 428-434.